Embody Insertional Achilles Tendinopathy
Terminated · NCT05998785
Conditions: Insertional Achilles Tendinopathy
At a glance
- Research payments reported, 2025
- $10,657
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 8
About the trial
- Sponsor
- Zimmer Biomet (with Embody Inc.)
- Tested
- TAPESTRY Biointegrative Implant (device)
- Dates
- Started 2022-08-02; completion 2024-08-01
- Results posted
- Not yet
The primary objective of this study is to evaluate the long-term effects on ankle/Achilles tendon pain after repair of insertional Achilles tendinopathy (IAT) augmented with TAPESTRY Biointegrative Implant.
From ClinicalTrials.gov, last updated 2024-12-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Zimmer Biomet Holdings, Inc. reported $10,657 in research payments for this study in 2025 (1 payments).
Products named: Tapestry
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $10,657
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.